Vivus Llc Drug Patent Portfolio
Vivus Llc owns 1 orange book drug protected by 11 US patents Given below is the list of Vivus Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity | 14 Jun, 2029 | Active |
| US8580298 | Low dose topiramate/phentermine composition and methods of use thereof | 15 May, 2029 | Active |
| US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity | 09 Jun, 2028 | Active |
| US8895058 | Low dose topiramate/phentermine composition and methods of use thereof | 09 Jun, 2028 | Active |
| US9011905 | Low dose topiramate/phentermine composition and methods of use thereof | 09 Jun, 2028 | Active |
| US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity | 09 Jun, 2028 | Active |
| US7056890 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7553818 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7659256 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7674776 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US6071537 | Anticonvulsant derivatives useful in treating obesity | 23 Jun, 2017 | Expired |
Latest Legal Activities on Vivus Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vivus Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011905 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011906 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895058 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895057 (Litigated) |
|
Expire Patent
Critical
| 11 Apr, 2022 | US7674776 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Oct, 2021 | US7674776 (Litigated) |
|
Expire Patent
Critical
| 02 Aug, 2021 | US7553818 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580299 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580298 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Feb, 2021 | US7553818 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 29 Jan, 2021 | US7553818 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Dec, 2020 | US8895058 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Dec, 2020 | US9011905 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Dec, 2020 | US8580298 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Dec, 2020 | US8580299 (Litigated) |
Vivus Llc's Family Patents
Vivus Llc drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 39.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Vivus Llc Drug List
Given below is the complete list of Vivus Llc's drugs and the patents protecting them.
1. Qsymia
Qsymia is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity |
14 Jun, 2029
(4 years from now)
| Active |
| US8580298 | Low dose topiramate/phentermine composition and methods of use thereof |
15 May, 2029
(4 years from now)
| Active |
| US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity |
09 Jun, 2028
(3 years from now)
| Active |
| US8895058 | Low dose topiramate/phentermine composition and methods of use thereof |
09 Jun, 2028
(3 years from now)
| Active |
| US9011905 | Low dose topiramate/phentermine composition and methods of use thereof |
09 Jun, 2028
(3 years from now)
| Active |
| US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity |
09 Jun, 2028
(3 years from now)
| Active |
| US7056890 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(4 years ago)
| Expired |
| US7553818 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(4 years ago)
| Expired |
| US7659256 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(4 years ago)
| Expired |
| US7674776 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(4 years ago)
| Expired |
| US6071537 | Anticonvulsant derivatives useful in treating obesity |
23 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qsymia's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List